Core for Life - a new European alliance in biomedical research: http://t.co/Hvv6P88kRt
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
Galapagos NV (Euronext: GLPG) announced today that it agreed with Roche to end their alliance in fibrosis. Roche will make a payment of €5.75 million to Galapagos for work completed in 2012, contributing to 2012 Group revenues. read more
Six of the world’s top translational health research centres today announced that they have come together to form a new Global Alliance of Leading Drug Discovery and Development Centres. The aim of this alliance is to strengthen the international academic and/or not-for-profit drug development and commercialization network to ultimately improve the rate at which academic research is translated into new medicines. read more
Ablynx [Euronext Brussels: ABLX] today announced a two-year extension of the initial five-year research funding by Boehringer Ingelheim of their global strategic alliance to discover, develop and commercialise up to 10 different Nanobody® therapeutics. The extension which will run until September 2014, will allow all the existing ten Nanobody programmes to advance to a stage where Boehringer Ingelheim can potentially progress each programme into development. Ablynx will receive a total of €6.6 million in additional research funding from Boehringer Ingelheim, some of which will be in advance. This payment is in return for work carried out by Ablynx's specialist Nanobody scientists. Ablynx has already received over €58 million from payments under the Strategic Alliance since it was signed in 2007. read more
The Hagen Desert Farming Project (HDFP), a humanitarian initiative designed for the most environmentally challenged northern states in Nigeria and the industrial crop technology company, QUINVITA announced today they have entered into a major strategic Jatropha development alliance. Under the signed agreement, as a member of the QUINVITA knowledge platforms for breeding, cultivar development and agronomy, HDFP will access the QUINVITA PRO (QVP) seed cultivars for planting in the project. Both companies agree that this relationship will provide the basis for an extensive collaboration on the testing and demonstration of different Jatropha lines, especially selected for adaptation to West‐Africa and appropriate agronomy, applicable by out‐growers who will be engaged by the HDFP. read more
Galapagos NV (Euronext: GLPG) announced today that investigational medicine GLPG0778, which is part of its immuno-inflammatory alliance with GlaxoSmithKline, has shown selective effects on a biomarker in a Phase I Proof-of-Mechanism study in healthy volunteers. The study also provided information on the safety and pharmacokinetic (PK) profile of GLPG0778. read more
Servier, a leading French pharmaceutical company, and Galapagos NV (Euronext: GLPG) announced today that they have entered into a multi-year strategic alliance to develop new therapies in osteoarthritis (OA). read more
FlandersBio, de Vlaamse sectororganisatie voor de life sciences en biotechnologie en de Amerikaanse biotechcluster Bio New Jersey (BioNJ) ondertekenden vorige week een samenwerkingspact met als doel hun activiteiten voor de sector samen af te stemmen. De ondertekening gebeurde in aanwezigheid van verschillende Vlaamse biotechbedrijven en vond plaats in Chicago tijdens BioUS, de grootste biotechbeurs ter wereld waar 15 322 biotechspelers van 49 staten en 65 landen vertegenwoordigd waren. read more
Galapagos NV (Euronext: GLPG) announced today that it has entered into a global multi-year strategic alliance with Roche (SIX: RO, ROG; OTCQX: RHHBY) to develop potential new therapies in COPD (chronic obstructive pulmonary disease). read more